Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-42

First 42 Last

Share
Profile

Follow
Stagflation

121 Posts.

46

09/11/23

08:47

Post #: 70799547
Share

Originally posted by dalts66: ↑

It is a huge ask. But lets look at it.

If this raise does its job, CHM are funded to have 3 drugs hitting arms in 4 trials. All those trials will have pivot data read outs before the money runs out. All the trials are novel drugs attacking disease with no effective SOC.

Read out from our GBM drug, if replicated, and there is no reason why it wont be, will lead to an accelerated approval trial.

This market cap does not represent where the company is. This helps to greatly derisk the investment. Directors are deferring payments get Focus available funds into progression of pipeline. This is huge for a small drug development bio tech.

Opportunity like this doesn't come around very often. Those that can afford to participate have the potential of many multiples of return, even with the dilution. Those that cant afford to participate, but hold onto there shares still have huge reward potential.

Raising this money is a very important step for the company. But its happening at a very difficult time, market wise.

We have the drugs, we have the people, we just need the cash.

Lets see how we go.

Expand

Any upcoming catalysts or news flow?

I saw a medtech company recently raise at all time lows and the stock jumped over 100% (has since settled around 50% higher) as they secured enough funds to reach FDA approval (or rejection) and other key milestones. Point is a similar situation could unfold here if they successfully raise the $10m with all future catalysts and impressive trial data so far.

Tough choice to wait for the SPP outcome or grab an initial parcel before...

CHM Price at posting: 2.7¢ Sentiment: Hold Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

There are more pages in this discussion • 15 more messages in this thread...

First 42 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.9¢		Change 0.001(2.70%)		Mkt cap ! $16.64M

Open	High	Low	Value	Volume
1.9¢	1.9¢	1.8¢	$12.15K	664.4K

Buyers (Bids)

No.	Vol.	Price($)
4	176666	1.8¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	226920	3

View Market Depth

No.	Vol.	Price($)
5	226666	0.018
6	1649367	0.017
10	2820994	0.016
9	4479999	0.015
5	2331428	0.014

Price($)	Vol.	No.
0.019	226920	3
0.020	1114755	4
0.021	631190	4
0.022	200000	1
0.023	150000	1

Last trade - 15.02pm 17/07/2024 (20 minute delay)

CHM (ASX) Chart

Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-42

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-42

Top Stories

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised

AI stocks: What to expect in 2024-25

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News